Form 8-K - Current report:
SEC Accession No. 0001140361-24-027994
Filing Date
2024-05-30
Accepted
2024-05-30 07:45:18
Documents
13
Period of Report
2024-05-24
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ef20030253_8k.htm   iXBRL 8-K 38421
  Complete submission text file 0001140361-24-027994.txt   177785

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20240524.xsd EX-101.SCH 3862
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20240524_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20240524_pre.xml EX-101.PRE 16042
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20030253_8k_htm.xml XML 4208
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 241000739
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)